3 results on '"Karlström, Patric"'
Search Results
2. Sodium‐glucose cotransporter 2 inhibitors are associated with reduced risk of mortality and readmissions in heart failure.
- Author
-
Karlström, Patric, Pivodic, Aldina, Dahlström, Ulf, and Fu, Michael
- Subjects
SODIUM-glucose cotransporter 2 inhibitors ,ALDOSTERONE antagonists ,GLUCOSE transporters ,PATIENT readmissions ,HEART failure ,COHORT analysis - Abstract
Aims: Compelling evidence from randomized trials has shown that sodium‐glucose cotransporter 2 inhibitors (SGLT2is) are effective in heart failure (HF) across the spectrum of left ventricular ejection fractions. However, there are very few studies with real‐world data. Methods and results: A retrospective cohort analysis was performed based on patient‐level data from the Swedish Heart Failure Registry (SwedeHF) linked with three other national registers. Patients included had an index registration between 3 September 2013 and 31 December 2020 in SwedeHF and were on treatment with guideline‐recommended therapy without or with SGLT2i 3 months before or 6 months after their index registration. Endpoints were mortality or readmissions. Association between the use of SGLT2i and endpoints was studied using adjusted Cox models. In the overall cohort, 796/22 405 patients were included with/without SGLT2i. In patients with SGLT2i, 93.5% had diabetes mellitus. In the overall cohort, SGLT2i was statistically significantly associated with all‐cause mortality {hazard ratio [HR]: 0.61 [95% confidence interval (CI) 0.48–0.79], P < 0.0001}, cardiovascular mortality [HR: 0.29 (95% CI 0.17–0.50), P < 0.0001], cardiovascular mortality or HF readmission [HR: 0.89 (95% CI 0.80–1.00), P = 0.046], and all‐cause readmissions [HR: 0.90 (95% CI 0.81–0.99), P = 0.038]. Similar results were obtained for the diabetes cohort. However, no association with cause‐specific readmissions was observed. Conclusions: This nationwide real‐world study indicates that patients with HF, in which majority coexisted with diabetes mellitus, who received SGLT2i were statistically significantly associated with lower risk for all‐cause mortality, cardiovascular mortality, cardiovascular mortality or HF readmissions, and all‐cause readmissions, in line with the randomized trials assessing SGLT2i. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
- Author
-
Yndigegn T, Lindahl B, Mars K, Alfredsson J, Benatar J, Brandin L, Erlinge D, Hallen O, Held C, Hjalmarsson P, Johansson P, Karlström P, Kellerth T, Marandi T, Ravn-Fischer A, Sundström J, Östlund O, Hofmann R, and Jernberg T
- Subjects
- Humans, Heart Failure etiology, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Secondary Prevention, Adrenergic beta-Antagonists adverse effects, Adrenergic beta-Antagonists therapeutic use, Bisoprolol adverse effects, Bisoprolol therapeutic use, Myocardial Infarction complications, Myocardial Infarction diagnostic imaging, Myocardial Infarction mortality, Myocardial Infarction therapy, Metoprolol adverse effects, Metoprolol therapeutic use
- Abstract
Background: Most trials that have shown a benefit of beta-blocker treatment after myocardial infarction included patients with large myocardial infarctions and were conducted in an era before modern biomarker-based diagnosis of myocardial infarction and treatment with percutaneous coronary intervention, antithrombotic agents, high-intensity statins, and renin-angiotensin-aldosterone system antagonists., Methods: In a parallel-group, open-label trial performed at 45 centers in Sweden, Estonia, and New Zealand, we randomly assigned patients with an acute myocardial infarction who had undergone coronary angiography and had a left ventricular ejection fraction of at least 50% to receive either long-term treatment with a beta-blocker (metoprolol or bisoprolol) or no beta-blocker treatment. The primary end point was a composite of death from any cause or new myocardial infarction., Results: From September 2017 through May 2023, a total of 5020 patients were enrolled (95.4% of whom were from Sweden). The median follow-up was 3.5 years (interquartile range, 2.2 to 4.7). A primary end-point event occurred in 199 of 2508 patients (7.9%) in the beta-blocker group and in 208 of 2512 patients (8.3%) in the no-beta-blocker group (hazard ratio, 0.96; 95% confidence interval, 0.79 to 1.16; P = 0.64). Beta-blocker treatment did not appear to lead to a lower cumulative incidence of the secondary end points (death from any cause, 3.9% in the beta-blocker group and 4.1% in the no-beta-blocker group; death from cardiovascular causes, 1.5% and 1.3%, respectively; myocardial infarction, 4.5% and 4.7%; hospitalization for atrial fibrillation, 1.1% and 1.4%; and hospitalization for heart failure, 0.8% and 0.9%). With regard to safety end points, hospitalization for bradycardia, second- or third-degree atrioventricular block, hypotension, syncope, or implantation of a pacemaker occurred in 3.4% of the patients in the beta-blocker group and in 3.2% of those in the no-beta-blocker group; hospitalization for asthma or chronic obstructive pulmonary disease in 0.6% and 0.6%, respectively; and hospitalization for stroke in 1.4% and 1.8%., Conclusions: Among patients with acute myocardial infarction who underwent early coronary angiography and had a preserved left ventricular ejection fraction (≥50%), long-term beta-blocker treatment did not lead to a lower risk of the composite primary end point of death from any cause or new myocardial infarction than no beta-blocker use. (Funded by the Swedish Research Council and others; REDUCE-AMI ClinicalTrials.gov number, NCT03278509.)., (Copyright © 2024 Massachusetts Medical Society.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.